These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35849287)

  • 1. Educational Review: Neoadjuvant Approaches to Melanoma.
    Sharon CE; Karakousis GC
    Ann Surg Oncol; 2022 Dec; 29(13):8492-8500. PubMed ID: 35849287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
    Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now.
    Long GV; Menzies AM; Scolyer RA
    J Clin Oncol; 2023 Jun; 41(17):3236-3248. PubMed ID: 37104746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach.
    Davar D; Tarhini AA; Kirkwood JM
    Clin Dermatol; 2013; 31(3):237-50. PubMed ID: 23608443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant systemic therapy in high-risk melanoma.
    Blankenstein SA; van Akkooi ACJ
    Melanoma Res; 2019 Aug; 29(4):358-364. PubMed ID: 30896556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
    Tarhini AA; Castellano E; Eljilany I
    Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials.
    Patel A; Skitzki J
    J Surg Oncol; 2022 Jan; 125(1):38-45. PubMed ID: 34897704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.
    van Akkooi ACJ; Zijlker LP; Wouters MWJM
    BioDrugs; 2022 May; 36(3):373-380. PubMed ID: 35397089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
    Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
    BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
    Pelster MS; Amaria RN
    Curr Treat Options Oncol; 2020 Feb; 21(2):10. PubMed ID: 32025932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift.
    Hieken TJ; Kreidieh F; Aedo-Lopez V; Block MS; McArthur GA; Amaria RN
    Am Soc Clin Oncol Educ Book; 2023 Jan; 43():e390614. PubMed ID: 37116111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.
    Lucas MW; Versluis JM; Rozeman EA; Blank CU
    Nat Rev Clin Oncol; 2023 Jun; 20(6):408-422. PubMed ID: 37147419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Therapy for Melanoma.
    Lowe MC; Kudchadkar RR
    Surg Oncol Clin N Am; 2020 Jul; 29(3):445-453. PubMed ID: 32482319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Localized Melanoma in the Anti-PD-1 Era.
    Novis E; van Akkooi ACJ
    Curr Oncol Rep; 2024 Aug; 26(8):924-933. PubMed ID: 38842606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma.
    Spagnolo F; Croce E; Boutros A; Tanda E; Cecchi F; Mascherini M; Solari N; Cafiero F; Queirolo P
    Expert Rev Anticancer Ther; 2020 May; 20(5):403-413. PubMed ID: 32326767
    [No Abstract]   [Full Text] [Related]  

  • 16. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Czarnecka AM; Ostaszewski K; Błoński PJ; Szumera-Ciećkiewicz A; Świtaj T; Kozak K; Koseła-Patreczyk H; Rogala P; Kalinowska I; Zaborowski K; Krotewicz M; Borkowska A; Rutkowski P
    Cancer; 2024 Oct; 130(20):3463-3472. PubMed ID: 38843386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Treatments for Advanced Resectable Melanoma.
    Liu JY; Lowe M
    J Surg Oncol; 2019 Jan; 119(2):216-221. PubMed ID: 30589079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative therapy in melanoma: Evolving perspectives in clinical trials.
    Kakish H; Xu K; Ahmed FA; Loftus AW; Elshami M; Hoehn RS; Ammori JB; Mangla A; Rothermel LD
    Crit Rev Oncol Hematol; 2024 Jan; 193():104193. PubMed ID: 37926375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.